Top-News

Regulus Therapeutics Inc News

Aktie
WKN:  A3DNZ4 ISIN:  US75915K3095 US-Symbol:  RGLS Branche:  Biotechnologie Land:  USA
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
14,42%
KGV
-2,25
Index-Zuordnung
-

Regulus Therapeutics Inc News

08.05.25 - PR Newswire
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates PR Newswire
06.05.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders PR Newswire
01.05.25 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, SWTX on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, SWTX on Behalf of Shareholders PR Newswire
30.04.25 - PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS PR Newswire
30.04.25 - PR Newswire
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG PR Newswire
02.04.25 - PR Newswire
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit PR Newswire
27.03.25 - PR Newswire
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-​Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal ...
04.03.25 - PR Newswire
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference
Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference PR Newswire
04.02.25 - PR Newswire
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference PR Newswire
29.01.25 - PR Newswire
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)
Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) ...

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »